| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198858 | Journal of Allergy and Clinical Immunology | 2011 | 15 Pages |
Abstract
Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved TH2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype.
Keywords
IVLFLGTh2CdsncorneodesmosinIDECANLRT-PCRNB-UVBAMPNarrow-band UVBFOXP3K16T22Real-time PCRLORImmunohistochemistryIHCNarrow-bandBiomarkerAtopic dermatitisinflammatory dendritic epidermal cellDendritic cellDEGPhototherapyfilaggrinLoricrinantimicrobial proteinforkhead box protein 3SkinDifferentially expressed genekeratin 16involucrin
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Suzanne BS, Avner MD, Mayte PhD, Hideki MD, PhD, Patricia MSN, FNP, Mary MSN, FNP, Leanne PhD, Andrea MD, Irma MSc, Shenghui MSc, Anne PhD, James G. MD, PhD, Emma MD, PhD,